Dr Pallavi Prasad, MD, DNB ( Nephrology)
@drpallaviprasad.bsky.social
📤 542
📥 118
📝 189
Nephrologist 🩺 Associate Professor 📚 Bookworm 🐛 Amateur gardener 🪴Travel enthusiast 🧳
🧩Solve the latest
#KidneyKolumns
crossword: NEPHRONS & NEOPLASIA 🦀🫘Test your knowledge of Onconephrology! 🌟First 5 correct entries will receive a shout-out in the next edition of
@isn-india.bsky.social
Newsletter Kidney Kolumns 🔗https://puzzel.org/en/crossword/play?p=-OvuDKCWauB8uMBaYYMQ
about 5 hours ago
0
0
1
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Swapnil Hiremath 🍁🇨🇦
about 14 hours ago
And
@nejm.org
retracts ADVOCATE based on the FDA uncovering and 2 academic authors asking for article to be pulled. (Good on them!)
www.nejm.org/doi/10.1056/...
h/t
@drjmluther.bsky.social
#Avacopan
#vasculitis
add a skeleton here at some point
1
13
9
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
6 days ago
#NephJC
Consensus From GEMRITUX, MENTOR, STARMEN, RI-CYCLO & MAJESTY- the signal remains consistent: ✅ Anti-CD20 therapy works ✅ Remissions are durable ✅ Relapses are lower than CNIs Check out anti-CD20 trials in pMN by
@nephroseeker.medsky.social
👇
#NephJC
#TenPostNephJC
#NephTwitter
#NephSky
1
8
2
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
NEJM.org
6 days ago
Among participants with rifampicin-resistant tuberculosis, a 6-month treatment strategy consisting of bedaquiline, linezolid, delamanid, and levofloxacin or clofazimine was noninferior to the standard treatment. Full phase 3 BEAT Tuberculosis trial results:
https://nej.md/4w7aekw
0
8
2
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
9 days ago
🚨New 🩳 by
@nephroseeker.medsky.social
eGFRcr, eGFRcys, eGFRcr-cys, mGFR... What does mGFR teach us about estimates and outcomes?
#NephSky
#MedSky
#NephJC
www.nephjc.com/news/2026/short/measuredgfr
loading . . .
NephJC Short: The map and the territory: what measured GFR teaches us about our estimates — NephJC
Is measured GFR more accurate than eGFR for forecasting adverse outcomes?
https://www.nephjc.com/news/2026/short/measuredgfr
0
14
9
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Swapnil Hiremath 🍁🇨🇦
8 days ago
Took us more than 10 years to get this to this stage AVF versus catheters - doing an RCT was difficult and we learnt a lot. Hope our community also does?
loading . . .
Comparing Catheters to Fistulas in Older Patients Starting... : Journal of the American Society of Nephrology
recommendations were based is observational with potential for bias. Methods A pilot randomized controlled trial was conducted in 12 hemodialysis centers in Canada and Australia. Individuals aged 55…
https://journals.lww.com/jasn/abstract/9900/comparing_catheters_to_fistulas_in_older_patients.1051.aspx
2
17
9
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Grace Choung, MD 박영이
12 days ago
Quantitative Serological Detection of NELL1 Autoantibodies in Membranous Nephropathy - Kidney International
www.kidney-international.org/article/S008...
loading . . .
Quantitative Serological Detection of NELL1 Autoantibodies in Membranous Nephropathy
Membranous nephropathy (MN) comprises distinct subtypes driven by autoantibodies targeting podocyte-associated proteins, one of which is neural EGFL like 1 (NELL1). Currently, the diagnosis of NELL1-a...
https://www.kidney-international.org/article/S0085-2538%2826%2900497-7/fulltext
0
5
2
Probenicid affects urate pathway and decreasing cyst growth in ADPKD Waiting to see how this area evolves in the future ! Dr Fouad Chebib is an inspiration..changing the landscape of ADPKD treatment!
add a skeleton here at some point
13 days ago
1
2
0
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Swapnil Hiremath 🍁🇨🇦
27 days ago
Huge effect of mTOR inhibition (sirolimus, everolimus?) in tuberous sclerosis
academic.oup.com/ckj/article/...
in
@ckj-era.bsky.social
Not an RCT of course - rare disease and all that! Via
@dguerrot.bsky.social
on LI
#NephSky
loading . . .
Real-world management of tuberous sclerosis complex–associated renal angiomyolipomas: the impact of mTOR inhibitors
ABSTRACTBackground. Renal angiomyolipomas (AMLs) drive substantial morbidity in tuberous sclerosis complex (TSC) through haemorrhage and repeated invasive
https://academic.oup.com/ckj/article/19/4/sfag072/8504126?login=false
1
8
5
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Swapnil Hiremath 🍁🇨🇦
26 days ago
Unlike COMPASS, TRACK demonstrates rivaroxaban doesn’t have the same CV benefit in CKD
jamanetwork.com/journals/jam...
Simultaneous pubs from
#ERA26
loading . . .
Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease
This randomized clinical trial examines the safety and efficacy of low-dose rivaroxaban in the treatment of patients with advanced chronic kidney disease at high risk for cardiovascular events.
https://jamanetwork.com/journals/jama/fullarticle/2850100
1
15
8
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Swapnil Hiremath 🍁🇨🇦
25 days ago
Simulpub number 6 at
#ERA26
Obi beats tacrolimus in membranous nephropathy
www.nejm.org/doi/full/10....
in NEJM No surprise after MENTOR
loading . . .
Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy | NEJM
Studies of obinutuzumab, a type II anti-CD20 antibody, have shown efficacy in the treatment of hematologic cancers and autoimmune diseases. An evaluation of the efficacy and safety of obinutuzumab ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2602678?query=RP
3
8
4
21/F G3P0LOA2 14weeks POG. Two 1st trimester abortions-cause? Incidental detection of urine alb. No HT 24 HR UP =1.3g/d s.creat=0.7 mg/dL Urine- no RBCs APLA,ANA negative, C3, C4 normal. Wud u do a biopsy ?
#NephSky
@shilpajesudason.bsky.social
@silvishah.bsky.social
@priti899.bsky.social
23 days ago
1
3
1
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
about 1 month ago
✨Exciting news
#NephtSky
The new
#NephJC
editorial interns are here! 📢Give them a follow and make them feel at home 👉
@drbarbateba.bsky.social
@ancast13.bsky.social
@kiddokidney.bsky.social
@andrewdelaat.bsky.social
@farahwehbe92.bsky.social
👇👇
www.nephjc.com/news/2025/6/...
loading . . .
NephJC Internship 2026-2027 — NephJC
Introducing NephJC’s brand new editorial internship class of 2026-2027
https://www.nephjc.com/news/2025/6/21/nephjc-internship-2026
1
19
14
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
3 months ago
1/10 Welcome to
#TenPostNephJC
Can we move beyond slowing CKD → to actually repairing the kidney? Last
#NephJC
we discussed Rilparencel, a renal autologous cell therapy (REACT) infusion and its effect on eGFR slope.
1
8
10
Hi everyone! Pallavi from New Delhi. No COI
#NephJC
Using flozins occasionally in transplants-mostly in those with proteinuria+-PTDM.
5 months ago
1
7
0
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Swapnil Hiremath 🍁🇨🇦
5 months ago
moving on from IgAN to FSGS: BI 764198 a TRPC6 inhibitor reduces proteinuria in an N = 67 phase 2 RCT
www.thelancet.com/journals/lan...
in
@thelancet.com
#NephSky
loading . . .
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198
BI 764198 lowered proteinuria and was well tolerated by participants in this trial. This is the first evidence of efficacy with a podocyte-targeted therapy in FSGS. Larger randomised controlled trials...
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02255-X/abstract?rss=yes
2
12
6
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
ASN Publications
5 months ago
Editors’ Choice 2025: Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial This phase 2 trial tested ravulizumab, a complement C5 inhibitor, in adults with IgA nephropathy. Check out the paper here:
kidney.pub/JASN0534
0
2
3
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
5 months ago
Sodium-Glucose Cotransporter-2 Inhibitors #SGLT2i and #Cardiorenal Events in #Nonalbuminuric Kidney Disease #VisualAbstract by
Augusto Cesar S Santos Jr
https://www.kireports.org/article/S2468-0249(25)00774-0/fulltext
#SGLT2i
#Cardiorenal
#Nonalbuminuric
#VisualAbstract
whuang0824
0
3
3
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
5 months ago
1/10 Last
#NephJC
we discussed Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN
#TenPostNephJC
Given the central role of complement dysregulation in C3 glomerulonephritis, we assessed whether complement-targeted therapies confer therapeutic benefit.
www.nejm.org/doi/full/10....
1
8
10
Hi everyone! Pallavi from New Delhi. No COI
#NephJC
6 months ago
3
5
0
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
6 months ago
Check out the VA for VALIANT from
@nephromommy-akshu.bsky.social
#NephJC
www.nephjc.com/news/2026/1/11/valiant-the-visual-abstract
loading . . .
VALIANT: The Visual Abstract — NephJC
The VALIANT phase 3 RCT shows that proximal C3 inhibition with pegcetacoplan leads to a significantly greater reduction in proteinuria compared with placebo in patients with C3G and primary immune-com...
https://www.nephjc.com/news/2026/1/11/valiant-the-visual-abstract
0
13
10
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
7 months ago
The LIBERATE-D VA by
@sejalplakhani.bsky.social
Should we break the pattern of thrice weekly dialysis in AKI-D?
#NephJC
#NephSky
www.nephjc.com/news/liberateva
loading . . .
LIBERATE-D: The Visual Abstract — NephJC
In patients with dialysis-dependent acute kidney injury, a conservative dialysis strategy was evaluated in the LIBERATE-D trial. Could less be more? Join the discussion in #NephJC, but first, check ou...
https://www.nephjc.com/news/liberateva
0
8
9
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
7 months ago
Join us for the last
#NephJC
of 2025, 12/16/25 at 9pm EST!🥳 How soon should we withhold dialysis in AKI? We're discussing the LIBERATE-D trial
#NephSky
This one might just change your mind 🧠🧠 Blog by
@msocomd.bsky.social
and
@sejalplakhani.bsky.social
www.nephjc.com/news/liberated-aki
loading . . .
Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D — NephJC
This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.
https://www.nephjc.com/news/liberated-aki
2
12
13
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
7 months ago
1/10 Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC Read the article 👇
www.nejm.org/doi/10....
#NephJC
1
9
9
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
7 months ago
T3f:
#NephJC
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA). Do you think either has the advantage?
2
12
7
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
7 months ago
T0k: #NephJC The 96-week extension demonstrated durability: ⬇️proteinuria fell 52% ⬇️Gd-IgA1 dropped 66% ⬇️hematuria declined 75% ⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m² ⚠️Safety: mild injection-site reactions and transient infections
pubmed.ncbi.nlm.nih....
#NephJC
1
9
5
Hi everyone! Pallavi from New Delhi ! The day light saving change in
#NephJC
doesn't help when in India - approaching time to leave for work..will be lurking . Excited about targeted therapeutic approaches in IgAN . No COI.
7 months ago
0
4
0
Day light saving always confuses me. One hour early for
#NephJC
🥲 and wondering where everyone else is! 😂
7 months ago
0
1
0
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
7 months ago
Check out the awesome visual abstract by
@salinesolut.bsky.social
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
loading . . .
ORIGIN-3: The Visual Abstract — NephJC
Atacicept, BAFF/APRIL inhibition in IgAN
https://www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
0
12
14
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
8 months ago
APRIL/BAFF inhibition: 🎯💊🩺 Trials are under way on this pathway, which promise to get to the root cause of IgAN. However, with great innovation comes…greater confusion. Sequence of treatment, cost, and side effects will need to be considered when increasing immunosuppression.
#NephJC
1
5
1
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Swapnil Hiremath 🍁🇨🇦
8 months ago
BTW super interesting basket trial from India (Ongoing)
bsky.app/profile/hswa...
Maybe they can eventually add a povetacicept arm 😏
#NephJC
add a skeleton here at some point
1
3
2
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
8 months ago
Treatment Approach: 💊 Novel therapies for IgAN have shifted the paradigm to a bi-pronged approach. a) Generic responses to HTN/proteinuria b) Fundamental drivers of nephron loss by reducing the formation of aberrant IgA molecules & the maladaptive mechanisms that contribute to CKD.
#NephJC
5
16
5
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
8 months ago
Let’s recapitulate the history and evidence-based developments of IgA Nephropathy. We’ve known about the pathologic etiology for decades, however there was a huge therapeutic plateau until quite recently. 💉💊 In the last few years, new therapies are coming up rapidly.
#NephJC
2
4
3
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
8 months ago
The 2025
@kdigo.org
IgAN guideline quietly redraws the map: new drugs, new thresholds, and a sense that the era of “supportive care only” is finally over
#Nephsky
#Medsky
✍️Summary by
@thekidneywhisperer.bsky.social
and
@glomerican.bsky.social
www.nephjc.com/news/igan-kd...
loading . . .
2025 IgAN KDIGO guidelines: fresh out of press, already aging gracefully — NephJC
This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy
https://www.nephjc.com/news/igan-kdigo-2025
1
22
16
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
8 months ago
⏩ Next
#NephJC
is on IgA nephropathy
@kdigo.org
guideline 🎨 Nice visual summary by
@roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
loading . . .
KDIGO 2025 IgA guidelines - Visual Abstract — NephJC
KDIGO 2025 is here. IgAN management is evolving with precision risk tools, new therapies, and a stronger focus on kidney protection. Check out the visual abstract created by Natalia Nombera
https://www.nephjc.com/news/2025/10/27/kdigo-2025-iga-guidelines-visual-abstract
0
20
18
Apart from myeloma and MGRS , what other diseases should we think of in case of increased UPCR with no albumunuria in urine analysis. Urine alb- trace UPCR-5.2 SIFE,SFLC - normal
@askrenal.bsky.social
#askrenal
#Nephsky
8 months ago
2
4
3
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
8 months ago
1/10 Last #NephJC we tried to answer the question whether protein supplementation increases health related QoL 🥩💊#TenPostNephJC . Read the article 👇
pubmed.ncbi.nlm.nih....
#NephJC
1
8
6
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
9 months ago
⏰30 min before the
#NephJC
chat Let's learn about the Gurus who paved the path to make kidney transplant “Mission Impossible to Mission Possible” with their research.
0
8
2
Hello everyone! Pallavi here from New Delhi. No COI.
#NephJC
9 months ago
1
4
0
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Jordy Cohen
10 months ago
www.nejm.org/doi/full/10....
There’s some trial data on prevention of albuminuria
#nephjc
loading . . .
Preventing Microalbuminuria in Type 2 Diabetes | NEJM
The multicenter double-blind, randomized Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) was designed to assess whether angiotensin-converting–enzyme inhibitors and non-dihydropyridine ...
https://www.nejm.org/doi/full/10.1056/NEJMoa042167
2
12
6
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
10 months ago
T2l Initiation of 2 first-line agents is still recommended for Stage 2 HTN but there is a new emphasis on using single-pill combinations. One pill goes down easier than two! What’s your favorite combo pill? Not using combo pills – what’s holding you back? #NephJC
www.thelancet.com/jo...
#NephJC
0
8
2
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
10 months ago
Check out the insightful VA that makes sense of the updates 🧠
#nephjc
VA by
@sejalplakhani.bsky.social
1
8
6
Hi everyone! Pallavi from New Delhi. no COI.
#NephJc
10 months ago
1
3
0
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
10 months ago
Finally, the concurrent results of the ALCHEMIST trial (
www.sciencedirect.co...
) also showed that spironolactone did not reduce major cardiovascular events in older, high-risk hemodialysis patients.
#NephJC
Infographic by @nephroseeker.medsky.socia
1
13
8
Hi everyone! Pallavi from New Delhi, joining
#Nephjc
after a long hiatus. lurking today .. No COI.
10 months ago
0
3
0
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
12 months ago
The
#NephJC
editorial team knows that plenty of papers deserve attention between our bi-monthly, full-length discussions ✨Enter
#NephJCShorts
- quick hits with a critical eye 🦅 on high-impact reads
www.nephjc.com/news/nephjc-...
#MedSky
#NephSky
loading . . .
Introducing NephJC Shorts — NephJC
In just over a decade of critical appraisal on NephJC, we have done several experiments. Some of them have worked out phenomenally well, such as the Freely Filtered podcast. Others were not ready for ...
https://www.nephjc.com/news/nephjc-shorts
0
11
11
#NephJC
add a skeleton here at some point
about 1 year ago
0
3
0
Hi everyone! Good morning from Kerala, God's own country. will be lurking today. COI: flozinator >> RAASblocker
about 1 year ago
2
3
1
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Michelle Rheault, MD
about 1 year ago
From Rivka Galchen’s article in
@newyorker.com
: “The kidney, a tremendously under-celebrated organ, basically does four-dimensional sudoku with ions.” And that’s how I’m going to explain it from now on.
1
36
10
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Swapnil Hiremath 🍁🇨🇦
about 1 year ago
Hilarious (and sobering) essay on the use of AI in medical research & manuscript writing Read the whole thing! John Daugirdas has been on the cutting edge of tech in meded before
#MedEd
was thing
onlinelibrary.wiley.com/doi/10.1111/...
#MedSky
#NephSky
loading . . .
Use of Artificial Intelligence in Scientific Writing. The Danger of Trying Too Hard to Please
The author describes his experience using several artificial intelligence programs to assist in the process of editing or preparing manuscripts for publication. While the programs were very useful to...
https://onlinelibrary.wiley.com/doi/10.1111/hdi.13270?af=R
4
19
15
Load more
feeds!
log in